Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
April 07 2009 - 2:03PM
PR Newswire (US)
- New offices in Chile and Peru, expansion of Argentina office
increase access to patients to reduce drug development timelines
for biopharmaceutical companies - PRINCETON, N.J., April 7
/PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced
the recent opening of new clinical development offices in Santiago,
Chile, and Lima, Peru, and the expansion of the company's Buenos
Aires, Argentina office. These latest office openings further
extend the company's global clinical development presence to
increase patient access and reduce clinical development timelines.
Covance has been providing clinical trial support in Latin America
since 1997 with the company's first office in Buenos Aires,
Argentina. Operations in Latin America expanded quickly with the
organization of an extensive and highly-trained network of regional
clinical trial monitors. The new clinical offices located in
Santiago and Lima will support staff in Chile and Peru, including
Covance's regional network of field-based clinical research
associates throughout Latin America. "Our strategy is to target
areas for qualified patient populations and the most qualified
investigators as we selectively expand our presence in key
metropolitan centers in emerging regions such as Latin America,"
said Katie Margules, Covance's senior director of project
management in Latin America. "Our focus continues to be on
delivering outstanding drug development and building stronger
strategic relationships with our clients." The new offices and
expanded facilities in Latin America will help Covance expedite the
execution of clinical studies with a full range of services, and
build strategic relationships with investigators, sites, and
regulatory authorities in a region known for its strong potential
to contribute to high-quality global clinical trial conduct. "We
are committed to continuing to build our infrastructure across
Latin America, expanding current facilities, and opening further
new clinical offices to increase Phase III clinical trial
productivity," said Wayne Langlois, Covance's vice president and
general manager of clinical development services, Americas. "These
countries offer qualified patient populations and investigators
which help reduce clinical development timelines for our
biopharmaceutical clients." Covance offers clinical development
services, including Phase I to IV clinical trial support in more
than 55 countries which include emerging markets across Asia
Pacific, Central and Eastern Europe, and Latin America. With a
full-suite of services to take a drug through all stages of drug
development, Covance offers extensive clinical and therapeutic
expertise, global reach, proactive project management, and strong
investigator site relationships to consistently deliver high
quality data on time. About Covance Covance, with headquarters in
Princeton, New Jersey, is one of the world's largest and most
comprehensive drug development services companies with annual
revenues greater than $1.5 billion, global operations in more than
25 countries, and more than 9,600 employees worldwide. Information
on Covance's products and services, recent press releases, and SEC
filings can be obtained through its website at
http://www.covance.com/. Statements contained in this press
release, which are not historical facts, are forward-looking
statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding
anticipated trends in the Company's business are based largely on
management's expectations and are subject to and qualified by risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation,
competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the
Company's ability to continue to attract and retain qualified
personnel, the fixed price nature of contracts or the loss of large
contracts, and other factors described in the Company's filings
with the Securities and Exchange Commission. DATASOURCE: Covance
Inc. CONTACT: Media Relations, +1-609-419-2466, or Investor
Relations, +1-609-452-4807 Web Site: http://www.covance.com/
Copyright